Baird analyst Jack Allen downgraded Decibel Therapeutics (DBTX) to Neutral from Outperform with a price target of $5.25, down from $21. The takeover by Regeneron (REGN) for $4.00 per share in cash and an additional $3.50 per share in contingent value rights seems likely to close on schedule, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on DBTX: